The Clinical Efficacy of Immunomodulators in RA Patients

Recruiting Phase 4 Interventional Study
Arthritis, Rheumatoid
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 80
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Treatment
Participants needed
400 (estimated)
Sponsor
Qilu Hospital of Shandong University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This study includes naive patients and csDMARDs-IR RA patients, treated with different regimens such as Iguratimod combination of different csDMARDs, or csDMARD with TNF inhibitors for 24 weeks. The disease activity and drug response will be observed. The immune disorder and synovial function will be evaluated at the same time.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: \- 1.Patients with RA who meet ACR 1987 rheumatoid arthritis classification criteria or ACR/EULAR 2010 rheumatoid arthritis Classification Criteria and have knee dysfunction. 1. ACR 1987 rheumatoid arthritis classification criteria 1. morning stiffness lasting at least 1 h…
Contacts

Qiang Shu, Dr.

0086-0531-82169654

shuqiang@sdu.edu.cn

CONTACT

Bingbing Ren

0086-18765361979

sdrenbingbing@163.com

CONTACT